Bavarian Nordic raises 2026 outlook on US vaccine deal
Bavarian Nordic raised its 2026 revenue outlook to up to 5.7 billion crowns after a US deal. It also lifted its annual EBITDA margin forecast to 28 percent.
Xurve View
Insights:
Xurve View
BAVARIAN NORDIC A/S raised its 2026 revenue guidance to 5.7B Danish crowns ($898.46M) following a $97M contract option from the United States. The previous outlook ranged from 5B to 5.2B Danish crowns. Increased U.S. stockpiling of freeze-dried smallpox vaccines improves the company's long-term margin profile.
